INCRETIN-BASED THERAPIES FOR
TYPE 2 DIABETES Mechanism-Based Strategies to Achieve Patient-Centered Care SEPTEMBER 6, 2013 SEPTEMBER 9, 2013 SEPTEMBER 19, 2013 OCTOBER 8, 2013 OCTOBER 16, 2013 OCTOBER 24, 2013 NOVEMBER 21, 2013 DECEMBER 5, 2013 DECEMBER 10, 2013 This activity is sponsored by
Princeton, New Jersey Denver, Colorado Boston, Massachusetts Tampa, Florida Rosemont, Illinois Raleigh, North Carolina New York, New York Baltimore, Maryland Los Angeles, California
Educational partner pmiCME
This activity is supported by an independent medical education grant from Bristol-Myers Squibb and AstraZeneca LP.
BMS-T2DM Workbook R1 Tampa.indd 2
10/4/13 4:49 PM
BMS-T2DM Workbook R1 Tampa.indd 2
10/4/13 4:49 PM
VIRTUAL PROFESSOR FACULTY
Jack L. Leahy, MD Prerecorded Professor of Medicine Chief, Division of Endocrinology, Diabetes and Metabolism University of Vermont Burlington, Vermont
PRESENTING FACULTY Lawrence Blonde, MD, FACP, FACE Director, Ochsner Diabetes Clinical Research Unit Department of Endocrinology Ochsner Medical Center New Orleans, Louisiana
Richard M. Bergenstal, MD Clinical Professor, Department of Medicine University of Minnesota Executive Director, International Diabetes Center Park Nicollet Minneapolis, Minnesota
Daniel Einhorn, MD, FACE, FACP Clinical Professor of Medicine University of California, San Diego Diabetes and Endocrine Associates Medical Director, Scripps Whittier Diabetes Institute La Jolla, California
Javier Morales, MD Vice President Principal Clinical Trials Investigator Advanced Internal Medicine Group, PC New Hyde Park, New York
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 3
3
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
FACULTY
Richard E. Pratley, MD Samuel E. Crockett, MD, Chair in Diabetes Research Professor, Sanford Burnham Medical Research Institute Medical Director, Florida Hospital Diabetes Institute Senior Scientist, Sanford Burnham Translational Research Institute Orlando, Florida
Mark W. Stolar, MD Associate Professor of Clinical Medicine Northwestern University Feinberg School of Medicine Chicago, Illinois
Jeffrey R. Unger, MD Assistant Professor of Family Medicine Loma Linda University School of Medicine Director of Metabolic Studies Catalina Research Institute Chino, California Not all faculty members will present in all cities. Faculty is subject to change, with additional faculty to be announced. *
4
BMS-T2DM Workbook R1 Tampa.indd 4
10/4/13 4:49 PM
LEARNING OBJECTIVES Upon completion of these educational activities, participants will be better prepared to: • Discuss the multisystem causes and consequences of type 2 diabetes mellitus (T2DM), including pathologic roles of the incretin pathways and the rationale for early diagnosis • Individualize treatment goals for patients with T2DM based on disease duration, age, relevant comorbidities, and ongoing evaluations of hemoglobin A1c levels and therapeutic responses
PREAMBLE
• Evaluate the mechanisms of action and clinical profiles of incretin-based therapies, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors • Develop and tailor personalized multimodal treatment plans for T2DM that include lifestyle interventions and incretin-based therapies alone or in combination with other antihyperglycemic medications • Educate diverse populations of patients with T2DM about lifestyle modifications, benefits and risks of various antihyperglycemic medications, and the importance of treatment adherence
TARGET AUDIENCE This activity is intended for primary care providers involved in the treatment and management of patients with type 2 diabetes mellitus.
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 5
5
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
6
BMS-T2DM Workbook R1 Tampa.indd 6
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 7
7
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
8
BMS-T2DM Workbook R1 Tampa.indd 8
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 9
9
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
10
BMS-T2DM Workbook R1 Tampa.indd 10
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 11
11
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
12
BMS-T2DM Workbook R1 Tampa.indd 12
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 13
13
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
14
BMS-T2DM Workbook R1 Tampa.indd 14
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 15
15
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
16
BMS-T2DM Workbook R1 Tampa.indd 16
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 17
17
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
18
BMS-T2DM Workbook R1 Tampa.indd 18
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 19
19
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
20
BMS-T2DM Workbook R1 Tampa.indd 20
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 21
21
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
22
BMS-T2DM Workbook R1 Tampa.indd 22
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 23
23
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
24
BMS-T2DM Workbook R1 Tampa.indd 24
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 25
25
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
26
BMS-T2DM Workbook R1 Tampa.indd 26
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 27
27
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
28
BMS-T2DM Workbook R1 Tampa.indd 28
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 29
29
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
30
BMS-T2DM Workbook R1 Tampa.indd 30
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 31
31
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
32
BMS-T2DM Workbook R1 Tampa.indd 32
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 33
33
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SLIDES
34
BMS-T2DM Workbook R1 Tampa.indd 34
10/4/13 4:49 PM
SLIDES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 35
35
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
SUGGESTED READING LIST American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care. 2012;35:S11-S63. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-837. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327-336. Grunberger G. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013. J Diabetes. 2013;5:241-253. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care. 2011;34(suppl 2):S251-S257. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33:1759-1765. Macconell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31-41.
SUGGESTED READING
Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013;125:7-20. Tschope D, Hanefeld M, Meier JJ, et al. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes. Cardiovasc Diabetol. 2013;12:62. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15:737-749.
36
BMS-T2DM Workbook R1 Tampa.indd 36
10/4/13 4:49 PM
NOTES
Mechanism-Based Strategies to Achieve Patient-Centered Care •
BMS-T2DM Workbook R1 Tampa.indd 37
37
10/4/13 4:49 PM
INCRETIN-BASED THERAPIES FOR TYPE 2 DIABETES
NOTES
38
BMS-T2DM Workbook R1 Tampa.indd 38
10/4/13 4:49 PM
BMS-T2DM Workbook R1 Tampa.indd 39
10/4/13 4:49 PM
For more information and to view additional resources for this program, please visit
EXCHANGECME.com/T2DMTHERAPIES
BMS-T2DM Workbook R1 Tampa.indd 1
10/4/13 4:49 PM